ChromaDex, 5LINX? in $62m ingredient agreement

ChromaDex Corporation^? has entered into a four-year ingredient supply and brand licensing agreement with direct marketing company 5LINX^?. Valued at $62 million, the deal grants 5LINX  marketing rights for ChromaDex's recently launched patented NIAGEN? Nicotinamide Riboside (NR) for use in dietary supplements exclusively in the network marketing sales channel in the United States, Canada and Philippines. 

Under the terms of agreement, 5LINX^? must purchase from ChromaDex $2.1 million of NIAGEN in 2014, and an aggregate of $46 million of NIAGEN from 2015 through 2017.  NIAGEN is the first and only commercially available brand of NR, which is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism.

5LINX^? has also been granted marketing rights for ChromaDex's patented PURENERGY? for use in dietary supplements, with select exclusively in the network marketing sales channel in the U.S., Canada and Philippines.  Under the exclusive network marketing channel agreement, 5LINX^? must purchase from ChromaDex $520,000 of PURENERGY in 2014 and an aggregate of $14 million of PURENERGY? from 2015 through 2017. PURENERGY caffeine alternative is a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure? pterostilbene, a potent anti-oxidant found in blueberries.